Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2024 | $18.00 | Buy | Craig Hallum |
5/14/2024 | $25.00 | Overweight | Stephens |
7/26/2022 | $17.00 | Buy | Canaccord Genuity |
12/10/2021 | $25.00 | Buy | H.C. Wainwright |
8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
S-8 - DELCATH SYSTEMS, INC. (0000872912) (Filer)
8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million HEPZATO KIT revenue of $19.2 million CHEMOSAT revenue of $1.3 million Gross margins expected to be 87% Net income of $0.8 million Positive adjusted EBITDA of $5.3 million Positive operating cashflow of approximately $4.8 mill
Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. CHOPIN Trial Design The investigator-initiated, prospective, randomized Phase 2 CHOPIN Trial was designed to compare the safety, tolerability, and efficacy of Delcath's CHEMOSAT® Hepatic Delivery Sy
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath's CHEMOSAT® Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastati
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00
Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00
Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she
Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million HEPZATO KIT revenue of $19.2 million CHEMOSAT revenue of $1.3 million Gross margins expected to be 87% Net income of $0.8 million Positive adjusted EBITDA of $5.3 million Positive operating cashflow of approximately $4.8 mill
Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. CHOPIN Trial Design The investigator-initiated, prospective, randomized Phase 2 CHOPIN Trial was designed to compare the safety, tolerability, and efficacy of Delcath's CHEMOSAT® Hepatic Delivery Sy
Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in the second quarter of 2024 CHEMOSAT® revenue of $1.7 million, compared to $1.2 million in the second quarter of 2024 Gross margins of 86%, compared to 80% in the second q
SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)
SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)
SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)
Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS
Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling
Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS